Overview

The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

Status:
Not yet recruiting

Trial end date:
2025-03-31

Target enrollment:

Participant gender:

Summary

A Prospective, Randomized, Open-Label, Multicenter Clinical Trial study to compare the efficacy and safety of ATRA plus eltrombopag compared to eltrombopag monotherapy in the treatment of steroid-resistant/relapsed immune thrombocytopenia (ITP).

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Collaborators:

Beijing Friendship Hospital
Beijing Hospital
Beijing Tongren Hospital
The Sixth Medical Center of PLA General Hospital

Treatments:

Tretinoin